Epilepsy - Pipeline Review, H1 2014
出 版 商：Global Markets Direct
出版日期：2014/02/28
頁 數：259頁
文件格式：PDF
價 格：
USD 2,000 (Single-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
Epilepsy - Pipeline Review, H1 2014
Summary
Global Markets Direct’s, ‘Epilepsy - Pipeline Review, H1 2014’, provides an overview of the Epilepsy’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Epilepsy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Epilepsy and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Epilepsy
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Epilepsy and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Epilepsy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Epilepsy pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Epilepsy
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Epilepsy pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Summary
Global Markets Direct’s, ‘Epilepsy - Pipeline Review, H1 2014’, provides an overview of the Epilepsy’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Epilepsy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Epilepsy and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Epilepsy
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Epilepsy and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Epilepsy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Epilepsy pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Epilepsy
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Epilepsy pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Epilepsy Overview 10
Therapeutics Development 11
Pipeline Products for Epilepsy - Overview 11
Pipeline Products for Epilepsy - Comparative Analysis 12
Epilepsy - Therapeutics under Development by Companies 13
Epilepsy - Therapeutics under Investigation by Universities/Institutes 18
Epilepsy - Pipeline Products Glance 20
Late Stage Products 20
Clinical Stage Products 21
Early Stage Products 22
Unknown Stage Products 23
Epilepsy - Products under Development by Companies 24
Epilepsy - Products under Investigation by Universities/Institutes 29
Epilepsy - Companies Involved in Therapeutics Development 30
Allergan, Inc. 30
Neurocrine Biosciences, Inc. 31
Novartis AG 32
Acorda Therapeutics, Inc. 33
Astellas Pharma Inc. 34
Chong Kun Dang Pharmaceutical Corp. 35
Eisai Co., Ltd. 36
H. Lundbeck A/S 37
Pfizer Inc. 38
UCB S.A. 39
Vertex Pharmaceuticals Incorporated 40
Sun Pharmaceutical Industries Limited 41
Impax Laboratories, Inc. 42
Aeolus Pharmaceuticals, Inc. 43
GW Pharmaceuticals plc 44
Anavex Life Sciences Corp. 45
Bionomics Limited 46
Zalicus Inc. 47
Paloma Pharmaceuticals, Inc. 48
Bio-Link Australia Pty. Ltd. 49
D-Pharm Ltd. 50
Upsher-Smith Laboratories, Inc. 51
Snowdon Inc. 52
Lipicard Technologies Limited 53
MedGenesis Therapeutix Inc. 54
Celentyx Ltd. 55
Concert Pharmaceuticals, Inc. 56
Knopp Biosciences LLC 57
Biovista Inc. 58
Asklepios BioPharmaceutical, Inc. 59
Marinus Pharmaceuticals, Inc. 60
Bial - Portela & Ca, S.A. 61
XERIS Pharmaceuticals, Inc. 62
MediProPharma, Inc. 63
Vichem Chemie Research Ltd. 64
Aestus Therapeutics, Inc. 65
Convergence Pharmaceuticals Ltd. 66
BioCrea GmbH 67
Advicenne Pharma 68
SciFluor Life Sciences, LLC 69
SK Biopharmaceuticals Co., Ltd. 70
Aniona ApS 71
Glialogix, Inc. 72
Epilepsy - Therapeutics Assessment 73
Assessment by Monotherapy Products 73
Assessment by Target 74
Assessment by Mechanism of Action 78
Assessment by Route of Administration 82
Assessment by Molecule Type 84
Drug Profiles 86
lacosamide - Drug Profile 86
perampanel - Drug Profile 90
eslicarbazepine acetate - Drug Profile 92
diazepam - Drug Profile 95
ADV-5803 - Drug Profile 96
lacosamide - Drug Profile 97
brivaracetam - Drug Profile 101
carbamazepine - Drug Profile 103
carisbamate - Drug Profile 105
diazepam - Drug Profile 107
eslicarbazepine acetate - Drug Profile 108
lacosamide - Drug Profile 111
everolimus - Drug Profile 115
belnacasan - Drug Profile 119
YKP-3089 - Drug Profile 120
naluzotan - Drug Profile 122
DP-VPA - Drug Profile 123
selurampanel - Drug Profile 125
ganaxolone - Drug Profile 126
IPX-218 - Drug Profile 128
topiramate - Drug Profile 129
tonabersat - Drug Profile 130
GWP-42006 - Drug Profile 131
SUN-44 - Drug Profile 132
INS-001 - Drug Profile 133
PF-04895162 - Drug Profile 134
CKD-903 - Drug Profile 135
ANAVEX-2-73 - Drug Profile 136
Antiepileptic Drugs - Drug Profile 138
ANAVEX-19-144 - Drug Profile 139
P-529 - Drug Profile 141
DP-VPA - Drug Profile 143
liatermin - Drug Profile 145
BVA-601 - Drug Profile 148
Program For Neurological Disorders - Drug Profile 149
AEOL-11207 - Drug Profile 150
C-10068 - Drug Profile 151
Z-944 - Drug Profile 153
Drug For Epilepsy - Drug Profile 154
VID-45110 - Drug Profile 155
ARA-290 - Drug Profile 156
BNP-TLE - Drug Profile 158
SL-327 - Drug Profile 159
Drug to Activate GABA Receptor for Epilepsy - Drug Profile 160
KM-314 - Drug Profile 161
KM-113 - Drug Profile 162
SF-0034 - Drug Profile 163
ADV-6770 - Drug Profile 164
2-DG - Drug Profile 165
ADV-6769 - Drug Profile 167
LT-4121 - Drug Profile 168
LT-4122 - Drug Profile 169
LT-4123 - Drug Profile 170
LT-4124 - Drug Profile 171
LT-4125 - Drug Profile 172
LT-4126 - Drug Profile 173
MRS-5474 - Drug Profile 174
GLX-1112 - Drug Profile 175
MPP-021 - Drug Profile 176
MPP-313 - Drug Profile 177
MPP-315 - Drug Profile 178
MPP-306 - Drug Profile 179
NAX-8102 - Drug Profile 180
Dynamin Inhibitor Program - Drug Profile 181
NAX-5055 - Drug Profile 182
Ketamine Analogue - Drug Profile 183
Cannabidivarin - Drug Profile 184
TLR-4 Antagonists for CNS Disorders - Drug Profile 186
MSP - Drug Profile 187
ESB - Drug Profile 188
EMSP - Drug Profile 189
ESBB - Drug Profile 190
SCT-66 - Drug Profile 191
VAD-1 - Drug Profile 192
VAD-2 - Drug Profile 193
VU-0456810 - Drug Profile 194
CNV-1061436 - Drug Profile 195
FV-082 - Drug Profile 196
Drugs Targeting Gamma-Amino Butyric Acid-A Receptor - Drug Profile 197
Drug Targeting Kv7.2 And Kv7.3 - Drug Profile 198
GABAA Receptor Modulators - Drug Profile 199
Gene Therapy For Epilepsy - Drug Profile 200
UBP-608 - Drug Profile 201
Methyl Pentanediol - Drug Profile 202
Potassium Channel Modulator - Drug Profile 203
diazepam XeriJect - Drug Profile 204
IPR-003 - Drug Profile 205
Kv7 Program - Drug Profile 206
Small Molecule to Target mGluR5 and mGluR6 for Central Nervous System Disorders - Drug Profile 207
CX-1010 - Drug Profile 208
PRTT-200 - Drug Profile 209
Epilepsy - Recent Pipeline Updates 210
Epilepsy - Dormant Projects 240
Epilepsy - Discontinued Products 241
Epilepsy - Product Development Milestones 242
Featured News & Press Releases 242
Appendix 251
Methodology 251
Coverage 251
Secondary Research 251
Primary Research 251
Expert Panel Validation 251
Contact Us 252
Disclaimer 252
List of Tables
Number of Products under Development for Epilepsy, H1 2014 18
Number of Products under Development for Epilepsy - Comparative Analysis, H1 2014 19
Number of Products under Development by Companies, H1 2014 21
Number of Products under Development by Companies, H1 2014 (Contd..1) 22
Number of Products under Development by Companies, H1 2014 (Contd..2) 23
Number of Products under Development by Companies, H1 2014 (Contd..3) 24
Number of Products under Investigation by Universities/Institutes, H1 2014 26
Comparative Analysis by Late Stage Development, H1 2014 27
Comparative Analysis by Clinical Stage Development, H1 2014 28
Comparative Analysis by Early Stage Development, H1 2014 29
Comparative Analysis by Unknown Stage Development, H1 2014 30
Products under Development by Companies, H1 2014 31
Products under Development by Companies, H1 2014 (Contd..1) 32
Products under Development by Companies, H1 2014 (Contd..2) 33
Products under Development by Companies, H1 2014 (Contd..3) 34
Products under Development by Companies, H1 2014 (Contd..4) 35
Products under Investigation by Universities/Institutes, H1 2014 36
Epilepsy - Pipeline by Allergan, Inc., H1 2014 37
Epilepsy - Pipeline by Neurocrine Biosciences, Inc., H1 2014 38
Epilepsy - Pipeline by Novartis AG, H1 2014 39
Epilepsy - Pipeline by Acorda Therapeutics, Inc., H1 2014 40
Epilepsy - Pipeline by Astellas Pharma Inc., H1 2014 41
Epilepsy - Pipeline by Chong Kun Dang Pharmaceutical Corp., H1 2014 42
Epilepsy - Pipeline by Eisai Co., Ltd., H1 2014 43
Epilepsy - Pipeline by H. Lundbeck A/S, H1 2014 44
Epilepsy - Pipeline by Pfizer Inc., H1 2014 45
Epilepsy - Pipeline by UCB S.A., H1 2014 46
Epilepsy - Pipeline by Vertex Pharmaceuticals Incorporated, H1 2014 47
Epilepsy - Pipeline by Sun Pharmaceutical Industries Limited, H1 2014 48
Epilepsy - Pipeline by Impax Laboratories, Inc., H1 2014 49
Epilepsy - Pipeline by Aeolus Pharmaceuticals, Inc., H1 2014 50
Epilepsy - Pipeline by GW Pharmaceuticals plc, H1 2014 51
Epilepsy - Pipeline by Anavex Life Sciences Corp., H1 2014 52
Epilepsy - Pipeline by Bionomics Limited, H1 2014 53
Epilepsy - Pipeline by Zalicus Inc., H1 2014 54
Epilepsy - Pipeline by Paloma Pharmaceuticals, Inc., H1 2014 55
Epilepsy - Pipeline by Bio-Link Australia Pty. Ltd., H1 2014 56
Epilepsy - Pipeline by D-Pharm Ltd., H1 2014 57
Epilepsy - Pipeline by Upsher-Smith Laboratories, Inc., H1 2014 58
Epilepsy - Pipeline by Snowdon Inc., H1 2014 59
Epilepsy - Pipeline by Lipicard Technologies Limited, H1 2014 60
Epilepsy - Pipeline by MedGenesis Therapeutix Inc., H1 2014 61
Epilepsy - Pipeline by Celentyx Ltd., H1 2014 62
Epilepsy - Pipeline by Concert Pharmaceuticals, Inc., H1 2014 63
Epilepsy - Pipeline by Knopp Biosciences LLC, H1 2014 64
Epilepsy - Pipeline by Biovista Inc., H1 2014 65
Epilepsy - Pipeline by Asklepios BioPharmaceutical, Inc., H1 2014 66
Epilepsy - Pipeline by Marinus Pharmaceuticals, Inc., H1 2014 67
Epilepsy - Pipeline by Bial - Portela & Ca, S.A., H1 2014 68
Epilepsy - Pipeline by XERIS Pharmaceuticals, Inc., H1 2014 69
Epilepsy - Pipeline by MediProPharma, Inc., H1 2014 70
Epilepsy - Pipeline by Vichem Chemie Research Ltd., H1 2014 71
Epilepsy - Pipeline by Aestus Therapeutics, Inc., H1 2014 72
Epilepsy - Pipeline by Convergence Pharmaceuticals Ltd., H1 2014 73
Epilepsy - Pipeline by BioCrea GmbH, H1 2014 74
Epilepsy - Pipeline by Advicenne Pharma, H1 2014 75
Epilepsy - Pipeline by SciFluor Life Sciences, LLC, H1 2014 76
Epilepsy - Pipeline by SK Biopharmaceuticals Co., Ltd., H1 2014 77
Epilepsy - Pipeline by Aniona ApS, H1 2014 78
Epilepsy - Pipeline by Glialogix, Inc., H1 2014 79
Assessment by Monotherapy Products, H1 2014 80
Number of Products by Stage and Target, H1 2014 83
Number of Products by Stage and Mechanism of Action, H1 2014 87
Number of Products by Stage and Route of Administration, H1 2014 90
Number of Products by Stage and Molecule Type, H1 2014 92
Epilepsy Therapeutics - Recent Pipeline Updates, H1 2014 217
Epilepsy - Dormant Projects, H1 2014 247
Epilepsy - Discontinued Products, H1 2014 248
List of Figures
Number of Products under Development for Epilepsy, H1 2014 18
Number of Products under Development for Epilepsy - Comparative Analysis, H1 2014 19
Number of Products under Development by Companies, H1 2014 20
Number of Products under Investigation by Universities/Institutes, H1 2014 25
Comparative Analysis by Late Stage Development, H1 2014 27
Comparative Analysis by Clinical Stage Development, H1 2014 28
Comparative Analysis by Early Stage Products, H1 2014 29
Assessment by Monotherapy Products, H1 2014 80
Number of Products by Top 10 Target, H1 2014 81
Number of Products by Stage and Top 10 Target, H1 2014 82
Number of Products by Top 10 Mechanism of Action, H1 2014 85
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 86
Number of Products by Top 10 Route of Administration, H1 2014 89
Number of Products by Stage and Top 10 Route of Administration, H1 2014 90
Number of Products by Top 10 Molecule Type, H1 2014 91
Number of Products by Stage and Top 10 Molecule Type, H1 2014 92
Table of Contents 2
List of Tables 6
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Epilepsy Overview 10
Therapeutics Development 11
Pipeline Products for Epilepsy - Overview 11
Pipeline Products for Epilepsy - Comparative Analysis 12
Epilepsy - Therapeutics under Development by Companies 13
Epilepsy - Therapeutics under Investigation by Universities/Institutes 18
Epilepsy - Pipeline Products Glance 20
Late Stage Products 20
Clinical Stage Products 21
Early Stage Products 22
Unknown Stage Products 23
Epilepsy - Products under Development by Companies 24
Epilepsy - Products under Investigation by Universities/Institutes 29
Epilepsy - Companies Involved in Therapeutics Development 30
Allergan, Inc. 30
Neurocrine Biosciences, Inc. 31
Novartis AG 32
Acorda Therapeutics, Inc. 33
Astellas Pharma Inc. 34
Chong Kun Dang Pharmaceutical Corp. 35
Eisai Co., Ltd. 36
H. Lundbeck A/S 37
Pfizer Inc. 38
UCB S.A. 39
Vertex Pharmaceuticals Incorporated 40
Sun Pharmaceutical Industries Limited 41
Impax Laboratories, Inc. 42
Aeolus Pharmaceuticals, Inc. 43
GW Pharmaceuticals plc 44
Anavex Life Sciences Corp. 45
Bionomics Limited 46
Zalicus Inc. 47
Paloma Pharmaceuticals, Inc. 48
Bio-Link Australia Pty. Ltd. 49
D-Pharm Ltd. 50
Upsher-Smith Laboratories, Inc. 51
Snowdon Inc. 52
Lipicard Technologies Limited 53
MedGenesis Therapeutix Inc. 54
Celentyx Ltd. 55
Concert Pharmaceuticals, Inc. 56
Knopp Biosciences LLC 57
Biovista Inc. 58
Asklepios BioPharmaceutical, Inc. 59
Marinus Pharmaceuticals, Inc. 60
Bial - Portela & Ca, S.A. 61
XERIS Pharmaceuticals, Inc. 62
MediProPharma, Inc. 63
Vichem Chemie Research Ltd. 64
Aestus Therapeutics, Inc. 65
Convergence Pharmaceuticals Ltd. 66
BioCrea GmbH 67
Advicenne Pharma 68
SciFluor Life Sciences, LLC 69
SK Biopharmaceuticals Co., Ltd. 70
Aniona ApS 71
Glialogix, Inc. 72
Epilepsy - Therapeutics Assessment 73
Assessment by Monotherapy Products 73
Assessment by Target 74
Assessment by Mechanism of Action 78
Assessment by Route of Administration 82
Assessment by Molecule Type 84
Drug Profiles 86
lacosamide - Drug Profile 86
perampanel - Drug Profile 90
eslicarbazepine acetate - Drug Profile 92
diazepam - Drug Profile 95
ADV-5803 - Drug Profile 96
lacosamide - Drug Profile 97
brivaracetam - Drug Profile 101
carbamazepine - Drug Profile 103
carisbamate - Drug Profile 105
diazepam - Drug Profile 107
eslicarbazepine acetate - Drug Profile 108
lacosamide - Drug Profile 111
everolimus - Drug Profile 115
belnacasan - Drug Profile 119
YKP-3089 - Drug Profile 120
naluzotan - Drug Profile 122
DP-VPA - Drug Profile 123
selurampanel - Drug Profile 125
ganaxolone - Drug Profile 126
IPX-218 - Drug Profile 128
topiramate - Drug Profile 129
tonabersat - Drug Profile 130
GWP-42006 - Drug Profile 131
SUN-44 - Drug Profile 132
INS-001 - Drug Profile 133
PF-04895162 - Drug Profile 134
CKD-903 - Drug Profile 135
ANAVEX-2-73 - Drug Profile 136
Antiepileptic Drugs - Drug Profile 138
ANAVEX-19-144 - Drug Profile 139
P-529 - Drug Profile 141
DP-VPA - Drug Profile 143
liatermin - Drug Profile 145
BVA-601 - Drug Profile 148
Program For Neurological Disorders - Drug Profile 149
AEOL-11207 - Drug Profile 150
C-10068 - Drug Profile 151
Z-944 - Drug Profile 153
Drug For Epilepsy - Drug Profile 154
VID-45110 - Drug Profile 155
ARA-290 - Drug Profile 156
BNP-TLE - Drug Profile 158
SL-327 - Drug Profile 159
Drug to Activate GABA Receptor for Epilepsy - Drug Profile 160
KM-314 - Drug Profile 161
KM-113 - Drug Profile 162
SF-0034 - Drug Profile 163
ADV-6770 - Drug Profile 164
2-DG - Drug Profile 165
ADV-6769 - Drug Profile 167
LT-4121 - Drug Profile 168
LT-4122 - Drug Profile 169
LT-4123 - Drug Profile 170
LT-4124 - Drug Profile 171
LT-4125 - Drug Profile 172
LT-4126 - Drug Profile 173
MRS-5474 - Drug Profile 174
GLX-1112 - Drug Profile 175
MPP-021 - Drug Profile 176
MPP-313 - Drug Profile 177
MPP-315 - Drug Profile 178
MPP-306 - Drug Profile 179
NAX-8102 - Drug Profile 180
Dynamin Inhibitor Program - Drug Profile 181
NAX-5055 - Drug Profile 182
Ketamine Analogue - Drug Profile 183
Cannabidivarin - Drug Profile 184
TLR-4 Antagonists for CNS Disorders - Drug Profile 186
MSP - Drug Profile 187
ESB - Drug Profile 188
EMSP - Drug Profile 189
ESBB - Drug Profile 190
SCT-66 - Drug Profile 191
VAD-1 - Drug Profile 192
VAD-2 - Drug Profile 193
VU-0456810 - Drug Profile 194
CNV-1061436 - Drug Profile 195
FV-082 - Drug Profile 196
Drugs Targeting Gamma-Amino Butyric Acid-A Receptor - Drug Profile 197
Drug Targeting Kv7.2 And Kv7.3 - Drug Profile 198
GABAA Receptor Modulators - Drug Profile 199
Gene Therapy For Epilepsy - Drug Profile 200
UBP-608 - Drug Profile 201
Methyl Pentanediol - Drug Profile 202
Potassium Channel Modulator - Drug Profile 203
diazepam XeriJect - Drug Profile 204
IPR-003 - Drug Profile 205
Kv7 Program - Drug Profile 206
Small Molecule to Target mGluR5 and mGluR6 for Central Nervous System Disorders - Drug Profile 207
CX-1010 - Drug Profile 208
PRTT-200 - Drug Profile 209
Epilepsy - Recent Pipeline Updates 210
Epilepsy - Dormant Projects 240
Epilepsy - Discontinued Products 241
Epilepsy - Product Development Milestones 242
Featured News & Press Releases 242
Appendix 251
Methodology 251
Coverage 251
Secondary Research 251
Primary Research 251
Expert Panel Validation 251
Contact Us 252
Disclaimer 252
List of Tables
Number of Products under Development for Epilepsy, H1 2014 18
Number of Products under Development for Epilepsy - Comparative Analysis, H1 2014 19
Number of Products under Development by Companies, H1 2014 21
Number of Products under Development by Companies, H1 2014 (Contd..1) 22
Number of Products under Development by Companies, H1 2014 (Contd..2) 23
Number of Products under Development by Companies, H1 2014 (Contd..3) 24
Number of Products under Investigation by Universities/Institutes, H1 2014 26
Comparative Analysis by Late Stage Development, H1 2014 27
Comparative Analysis by Clinical Stage Development, H1 2014 28
Comparative Analysis by Early Stage Development, H1 2014 29
Comparative Analysis by Unknown Stage Development, H1 2014 30
Products under Development by Companies, H1 2014 31
Products under Development by Companies, H1 2014 (Contd..1) 32
Products under Development by Companies, H1 2014 (Contd..2) 33
Products under Development by Companies, H1 2014 (Contd..3) 34
Products under Development by Companies, H1 2014 (Contd..4) 35
Products under Investigation by Universities/Institutes, H1 2014 36
Epilepsy - Pipeline by Allergan, Inc., H1 2014 37
Epilepsy - Pipeline by Neurocrine Biosciences, Inc., H1 2014 38
Epilepsy - Pipeline by Novartis AG, H1 2014 39
Epilepsy - Pipeline by Acorda Therapeutics, Inc., H1 2014 40
Epilepsy - Pipeline by Astellas Pharma Inc., H1 2014 41
Epilepsy - Pipeline by Chong Kun Dang Pharmaceutical Corp., H1 2014 42
Epilepsy - Pipeline by Eisai Co., Ltd., H1 2014 43
Epilepsy - Pipeline by H. Lundbeck A/S, H1 2014 44
Epilepsy - Pipeline by Pfizer Inc., H1 2014 45
Epilepsy - Pipeline by UCB S.A., H1 2014 46
Epilepsy - Pipeline by Vertex Pharmaceuticals Incorporated, H1 2014 47
Epilepsy - Pipeline by Sun Pharmaceutical Industries Limited, H1 2014 48
Epilepsy - Pipeline by Impax Laboratories, Inc., H1 2014 49
Epilepsy - Pipeline by Aeolus Pharmaceuticals, Inc., H1 2014 50
Epilepsy - Pipeline by GW Pharmaceuticals plc, H1 2014 51
Epilepsy - Pipeline by Anavex Life Sciences Corp., H1 2014 52
Epilepsy - Pipeline by Bionomics Limited, H1 2014 53
Epilepsy - Pipeline by Zalicus Inc., H1 2014 54
Epilepsy - Pipeline by Paloma Pharmaceuticals, Inc., H1 2014 55
Epilepsy - Pipeline by Bio-Link Australia Pty. Ltd., H1 2014 56
Epilepsy - Pipeline by D-Pharm Ltd., H1 2014 57
Epilepsy - Pipeline by Upsher-Smith Laboratories, Inc., H1 2014 58
Epilepsy - Pipeline by Snowdon Inc., H1 2014 59
Epilepsy - Pipeline by Lipicard Technologies Limited, H1 2014 60
Epilepsy - Pipeline by MedGenesis Therapeutix Inc., H1 2014 61
Epilepsy - Pipeline by Celentyx Ltd., H1 2014 62
Epilepsy - Pipeline by Concert Pharmaceuticals, Inc., H1 2014 63
Epilepsy - Pipeline by Knopp Biosciences LLC, H1 2014 64
Epilepsy - Pipeline by Biovista Inc., H1 2014 65
Epilepsy - Pipeline by Asklepios BioPharmaceutical, Inc., H1 2014 66
Epilepsy - Pipeline by Marinus Pharmaceuticals, Inc., H1 2014 67
Epilepsy - Pipeline by Bial - Portela & Ca, S.A., H1 2014 68
Epilepsy - Pipeline by XERIS Pharmaceuticals, Inc., H1 2014 69
Epilepsy - Pipeline by MediProPharma, Inc., H1 2014 70
Epilepsy - Pipeline by Vichem Chemie Research Ltd., H1 2014 71
Epilepsy - Pipeline by Aestus Therapeutics, Inc., H1 2014 72
Epilepsy - Pipeline by Convergence Pharmaceuticals Ltd., H1 2014 73
Epilepsy - Pipeline by BioCrea GmbH, H1 2014 74
Epilepsy - Pipeline by Advicenne Pharma, H1 2014 75
Epilepsy - Pipeline by SciFluor Life Sciences, LLC, H1 2014 76
Epilepsy - Pipeline by SK Biopharmaceuticals Co., Ltd., H1 2014 77
Epilepsy - Pipeline by Aniona ApS, H1 2014 78
Epilepsy - Pipeline by Glialogix, Inc., H1 2014 79
Assessment by Monotherapy Products, H1 2014 80
Number of Products by Stage and Target, H1 2014 83
Number of Products by Stage and Mechanism of Action, H1 2014 87
Number of Products by Stage and Route of Administration, H1 2014 90
Number of Products by Stage and Molecule Type, H1 2014 92
Epilepsy Therapeutics - Recent Pipeline Updates, H1 2014 217
Epilepsy - Dormant Projects, H1 2014 247
Epilepsy - Discontinued Products, H1 2014 248
List of Figures
Number of Products under Development for Epilepsy, H1 2014 18
Number of Products under Development for Epilepsy - Comparative Analysis, H1 2014 19
Number of Products under Development by Companies, H1 2014 20
Number of Products under Investigation by Universities/Institutes, H1 2014 25
Comparative Analysis by Late Stage Development, H1 2014 27
Comparative Analysis by Clinical Stage Development, H1 2014 28
Comparative Analysis by Early Stage Products, H1 2014 29
Assessment by Monotherapy Products, H1 2014 80
Number of Products by Top 10 Target, H1 2014 81
Number of Products by Stage and Top 10 Target, H1 2014 82
Number of Products by Top 10 Mechanism of Action, H1 2014 85
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 86
Number of Products by Top 10 Route of Administration, H1 2014 89
Number of Products by Stage and Top 10 Route of Administration, H1 2014 90
Number of Products by Top 10 Molecule Type, H1 2014 91
Number of Products by Stage and Top 10 Molecule Type, H1 2014 92
